(Q39730719)

14 September 2017

1 reference

title

Fluorinated quinolones. A review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy (English)

1 reference

14 September 2017

0 references

1 reference

Janknegt R

1

1 reference

14 September 2017

publication date

1 February 1986

1 reference

Pharmaceutisch weekblad. Scientific edition

14 September 2017

published in

1 reference

14 September 2017

volume

8

1 reference

14 September 2017

issue

1

1 reference

14 September 2017

page(s)

1-21

1 reference

Nalidixic Acid: an Antibacterial Paradox

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

In vitro activity of ciprofloxacin (Bay o 9867)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

In vitro and in vivo antibacterial activities of the fluoroquinolone WIN 49375 (amifloxacin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Comparative in vitro activity of ciprofloxacin against Campylobacter spp. and other bacterial enteric pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Comparative activity of ciprofloxacin against anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Effect of inoculum, pH, and medium on the activity of ciprofloxacin against anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Comparison of the in vitro activities of ofloxacin and tetracycline against Chlamydia trachomatis as assessed by indirect immunofluorescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Amifloxacin activity against well-defined gentamicin-resistant, gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

In vitro susceptibilities of 393 recent clinical isolates to WIN 49375, cefotaxime, tobramycin, and piperacillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

In-vitro activity of enoxacin against aminoglycoside-resistant gram-negative bacilli and other clinical isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Effects of changes in pH, medium, and inoculum size on the in vitro activity of amifloxacin against urinary isolates of Staphylococcus saprophyticus and Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Pharmacokinetics of intravenously administered ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Pharmacokinetics and tissue penetration of ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Pharmacokinetics of ciprofloxacin after oral and parenteral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Penetration of pefloxacin into cerebrospinal fluid of patients with meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Comparison of ciprofloxacin with azlocillin plus tobramycin in the therapy of experimental Pseudomonas aeruginosa endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Open, prospective study of the clinical efficacy of ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Norfloxacin, amoxycillin, cotrimoxazole and nalidixic acid: A summary of 3-day and 7-day therapy studies in the treatment of urinary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

The treatment of Pseudomonas aeruginosa urinary tract infections with norfloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Comparative trial of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localized, acute, symptomatic urinary tract infections and antimicrobial effect on periurethral and fecal microflora

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Comparative study using norfloxacin and amoxycillin in the treatment of complicated urinary tract infections in geriatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975473

In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents

21 January 2018

1 reference

12 December 2020

The clinical pharmacokinetics and tolerance of enoxacin in healthy volunteers

1 reference

12 December 2020

Reduced enteral absorption of ciprofloxacin in the presence of antacids

1 reference

12 December 2020

Activity of ciprofloxacin (BAYo 9867) against Pseudomonas aeruginosa and ampicillin-resistant Enterobacteriaceae

1 reference

12 December 2020

Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function--some preliminary results

1 reference

12 December 2020

The pharmacokinetics and tissue penetration of norfloxacin

1 reference

12 December 2020

Activities of newer quinolones against Legionella group organisms

1 reference

12 December 2020

The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.

1 reference

12 December 2020

Enoxacin raises plasma theophylline concentrations

1 reference

12 December 2020

Ciprofloxacin distribution in prostatic tissue and fluid following oral administration

1 reference

12 December 2020

Resistance to ciprofloxacin.

1 reference

12 December 2020

Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers

1 reference

12 December 2020

Intraprostatic concentrations of ciprofloxacin after intravenous administration

1 reference

12 December 2020

[Ciprofloxacine: evaluation of its biliary elimination in man]

1 reference

12 December 2020

Assessment of the in vitro and in vivo activity of ciprofloxacin measured against current standards of therapy.

1 reference

12 December 2020

Efficacy and safety of ciprofloxacin (Bay 0 9867) in the treatment of patients with complicated urinary tract infections.

1 reference

12 December 2020

In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid

1 reference

12 December 2020

Norfloxacin in acute urinary tract infections

1 reference

12 December 2020

Control of burn wound infections by pefloxacin and its silver derivative

1 reference

12 December 2020

Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase

1 reference

12 December 2020

Sisomicin, netilmicin and dibekacin. A review of their antibacterial activity and therapeutic use.

1 reference

12 December 2020

Dose- and sex-independent disposition of ciprofloxacin

1 reference

12 December 2020

Comparison of the antibacterial in vitro and in vivo activity of ofloxacin (HOE 280 DL 8280) and nalidixic acid analogues

1 reference

12 December 2020

In vitro activity of ciprofloxacin against mycobacteria

1 reference

12 December 2020

Comparative in-vitro activity of quinolone carboxylic acids against Proteeae.

1 reference

12 December 2020

In vitro activity of ciprofloxacin, azthreonam and ceftazidime against Serratia marcescens and Pseudomonas aeruginosa

1 reference

12 December 2020

Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA.

1 reference

12 December 2020

Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans

1 reference

12 December 2020

Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy

1 reference

12 December 2020

In vitro activity of ciprofloxacin against Bacteroides, Haemophilus influenzae and Branhamella catarrhalis

1 reference

12 December 2020

Influence of pH and human urine on the antibacterial activity of ciprofloxacin, norfloxacin and ofloxacin

1 reference

12 December 2020

DNA gyrase: an enzyme that introduces superhelical turns into DNA

1 reference

12 December 2020

Pharmacokinetics of norfloxacin in renal failure

1 reference

12 December 2020

Quinolones and raised plasma concentrations of theophylline

1 reference

12 December 2020

Activity of the newer quinolones against Chlamydia trachomatis

1 reference

12 December 2020

Enoxacin: worldwide in-vitro activity against 22451 clinical isolates

1 reference

12 December 2020

A laboratory assessment of ciprofloxacin and comparable antimicrobial agents

1 reference

12 December 2020

The pharmacokinetics and tissue penetration of ofloxacin

1 reference

12 December 2020

[Comparison of the antimicrobial activity of pefloxacin (1589 RB), nalidixic acid and flumequin (author's transl)].

1 reference

12 December 2020

Activity of ciprofloxacin against genital tract pathogens

1 reference

12 December 2020

Mutational resistance to 4-quinolone antibacterial agents

1 reference

12 December 2020

In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams.

1 reference

12 December 2020

[The antibacterial activity in vitro of ofloxacin in comparison with other orally administered antimicrobial substances on ampicillin-resistant clinical isolates]

1 reference

12 December 2020

In-vitro studies with ciprofloxacin, a new 4-quinolone compound.

1 reference

12 December 2020

In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid

1 reference

12 December 2020

Comparative in vitro studies with 4-quinolone antimicrobials

1 reference

12 December 2020

Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants.

1 reference

12 December 2020

Clinical resistance to long-term oral ciprofloxacin.

1 reference

12 December 2020

Intraprostatic concentration of ciprofloxacin and its activity against urinary pathogens

1 reference

12 December 2020

Norfloxacin versus cotrimoxazole in the treatment of uncomplicated urinary tract infections--a multi-centre trial

1 reference

12 December 2020

The activity of ciprofloxacin and other 4-quinolones againstChlamydia trachomatis andMycoplasmas in vitro

1 reference

12 December 2020

The pharmacokinetics and tissue penetration of enoxacin and norfloxacin

1 reference

12 December 2020

Novel amino-substituted 3-quinolinecarboxylic acid antibacterial agents: synthesis and structure-activity relationships

1 reference

12 December 2020

In vitro activity of enoxacin compared with norfloxacin and amikacin.

1 reference

12 December 2020

Multiple-dose ciprofloxacin kinetics in normal subjects

1 reference

12 December 2020

Susceptibility of Legionella spp. to quinolone derivatives and related organic acids

1 reference

12 December 2020

In vitro activity of amifloxacin against Chlamydia trachomatis and Ureaplasma urealyticum

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01975473

1 reference

14 September 2017

1 reference